Zobrazeno 1 - 10
of 43
pro vyhledávání: '"N I Gaponova"'
Autor:
N I Gaponova, V R Abdrakhmanov
Publikováno v:
Системные гипертензии, Vol 13, Iss 3, Pp 64-68 (2016)
The review shows the results of the use of prolonged release verapamil (Isoptin® SR) in clinical practice. Numerous randomized clinical studies confirm the high efficiency and safety of Isoptin® SR in patients with arterial hypertension, as well as
Externí odkaz:
https://doaj.org/article/3cd01e8d795c49058884c2db66f3daf4
Autor:
E A Chumakova, N I Gaponova
Publikováno v:
Системные гипертензии, Vol 11, Iss 2, Pp 5-8 (2014)
The aim of the study was to investigate the relationship of psychological and social characteristics of patients with hypertension often seek emergency medical help with their adherence to treatment.Material and methods. Outpatient were examined 300
Externí odkaz:
https://doaj.org/article/af69b4c3a53f4094bdc8f710433614a3
Autor:
N. I. Gaponova, V. R. Abdrakhmanov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 20, Iss 3, Pp 340-348 (2024)
Activation of the sympathetic nervous system plays an important role in arterial hypertension (AH) development. Antihypertensive drugs of central action contribute to the elimination of sympathetic activation. The selective imidazoline receptor agoni
Externí odkaz:
https://doaj.org/article/188b242ad29f4153b25e1cabf3d3ebce
Publikováno v:
Системные гипертензии, Vol 10, Iss 1, Pp 40-47 (2013)
Aim. To evaluate the clinical efficacy and safety of the selective imidazoline I1-receptor agonist moxonidine versus the angiotensin-converting enzyme inhibitor captopril in patients with uncomplicated hypertensive crisis (UHC). Subjects and methods.
Externí odkaz:
https://doaj.org/article/ec90269074274395b3305634eaa27a13
Publikováno v:
Системные гипертензии, Vol 8, Iss 4, Pp 32-39 (2011)
Externí odkaz:
https://doaj.org/article/45542250ca904c19b86dd33014167c9c
Autor:
S N Tereshchenko, V R Abdrakhmanov, N I Gaponova, T M Uskach, I V Kostsina, V V Skibitskiy, Zh D Kobalava, N Kh Bagmanova, Yu I Grinshteyn, V V Shabalin, L N Pletneva, Yu M Lopatin, AOKonradi RS Karpov, V F Mordovin, E V Tsymbalyuk, E A Shutemova, A R Kiselev
Publikováno v:
Системные гипертензии, Vol 7, Iss 4, Pp 48-53 (2010)
Externí odkaz:
https://doaj.org/article/8672eb79838748c59efb4126f22950d8
Publikováno v:
Современная ревматология, Vol 0, Iss 2, Pp 71-72 (2008)
Externí odkaz:
https://doaj.org/article/981a04e26a954060a0f234ddbc6b1c68
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 14, Iss 6, Pp 951-957 (2019)
Aim. Investigation of comparative dissolution kinetics of generic medicinal products containing moxonidine versus reference drug. Material and methods. Objects of the research were film-coated tablets containing moxonidine (INN) in a dose 0.4 mg: a r
Externí odkaz:
https://doaj.org/article/e6480de80b21477b8c38c63b8ba94848
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 8, Iss 1, Pp 57-60 (2015)
Aim. To assess the changes in the costs of treatment of patients with hypertensive crisis (HC) in pre-admission care in Moscow from 2005 to 2010. Material and methods. Comparative analysis of the treatment costs was performed depending on outcomes in
Externí odkaz:
https://doaj.org/article/762be4fc27774558a21b688ebfe994a3
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 8, Iss 5, Pp 703-707 (2015)
Results of experimental and clinical studies devoted to urapidil combining central antihypertensive effect with peripheral vasodilatation are discussed. Scope of urapidil application is described; its good tolerability and safety are highlighted. Ura
Externí odkaz:
https://doaj.org/article/47ae400ceb9b4cbca59ad771de6dfac1